New results build on previous positive data and supports the further development of TRX-1002 as a potential treatment candidate BOSTON, Nov. 14, 2022 /PRNewswire/ -- Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, today announced that its lead candidate for idiopathic pulmonary fibrosis (IPF), TXR-1002, demonstrated significant efficacy in new preclinical research. TXR-1002 represents a completely new novel mechanism of action for the potential treatment of IPF. Data was presented at the 6th Annual Antifibrotic Drug Development Summit on November 10 in Boston. This is the third preclinical study to validate the efficacy and safety of TXR-1002. Two previous studies evaluated TXR-1002 using a bleomycin-induced (BLM) IPF mouse model, the current best practice for IPF preclinical research, and demonstrated a significant decrease in fibrosis and lung collagen staining compared nintedanib, a standard of care. Aria completed a third study in therapeutic treatment mode utilizing a BLM-induced model in male Sprague Dawley rats, which have more complex airway anatomy than that of a traditional mouse, helping to further support the efficacy of TXR-1002's novel mechanism of action. "We continue to see promising data for our IPF candidate TXR-1002, validating our efforts to advance this program toward IND-enabling studies," said Anjali Pandey, Ph.D. Senior Vice President of Nonclinical R&D and Chemistry at Aria. "This is our third robust preclinical study for TXR-1002 that showed positive results and by utilizing a more advanced rat model. We are confident in the promise of this treatment as a viable candidate for clinical research." IPF is a chronic, age-associated interstitial lung disease characterized by progressive and irreversible fibrosis. It affects more than three million people worldwide. Though IPF's cause is still unknown, recent data suggest that IPF prevalence is increasing. "People suffering from IPF need new and novel treatments because while today's treatments slow disease progression, they do not stop it and are associated with a high rate of discontinuation," said Martin Kolb, M.D., Ph.D., Director, Division of Respirology and Jack Gauldie Boehringer Ingelheim Chair in Interstitial Lung Disease, Department of Medicine, McMaster University. "The incidence and burden of IPF are increasing globally, so discovering and developing new treatments needs to be a priority." To date, Aria has advanced potential treatments for chronic kidney disease (CKD), lupus, and IPF through preclinical research and now into lead optimization in preparation for IND-enabling studies. Aria is committed to advancing TXR-1002 and is continuing to research this promising therapy as a potential novel treatment for IPF. For more information, please visit About the study The efficacy of TXR-1002 was assessed in a dose response curve mode at 3, 10, 30 and 100 mg/kg once a day dosing in BLM-induced IPF in male Sprague Dawley rats. The study design included a placebo group, a BLM-induced IPF disease control group, four groups of a TXR-1002 treatment arm and a ninteanib treatment group. Following bleomycin administration, the absolute lung weight and hydroxyproline levels were significantly increased and histopathology data showed both Ashcroft score (measure of lung fibrosis) and collagen significantly increased in the BLM-induced IPF disease control group. TXR-1002 at 10, 30 and 100 mg/kg once a day administered orally significantly decreased absolute lung weight and hydroxyproline levels as compared to the disease control group. Treatment with TXR-1002 at 10, 30, 100 mg/kg in lung histopathology demonstrated significantly decreased fibrosis score and collagen similar to the nintedanib treatment group at 60 mg/kg. Full study results can be found at . About IPF Idiopathic pulmonary fibrosis (IPF) is a chronic, age-associated interstitial lung disease characterized by progressive fibrosis that leads to dyspnea and low forced vital capacity of the lungs. Inflammation is an additional feature of IPF, and the chronic, progressive nature of the disease presents challenges for developing effective therapies. Currently, there is no cure for IPF and existing FDA-approved treatments do not stop disease progression. About Aria Pharmaceuticals Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients today are in need of breakthrough treatments across many complicated diseases – they can't wait. That's why at Aria, we have redefined the drug discovery approach, saving years in the process and increasing success rates 30 times higher than traditional methods. At Aria, we've shown promise across a diverse range of therapeutic areas with the ability to address over 1,000 diseases. Contact Serena Joshi Aria Pharmaceuticals [email protected] SOURCE Aria Pharmaceuticals

临床结果

2022-08-30

·PRNewswire

Aria Pharmaceuticals Advances Pipeline with Six Provisional US Patents Filed Across Three Diseases

Patents filed for the company's most advanced programs in lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD)All novel mechanisms of action have demonstrated positive efficacy data in industry standard animal pharmacology models PALO ALTO, Calif., Aug. 30, 2022 /PRNewswire/ -- Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, announced that the company has successfully filed a total of six provisional patents with the United States Patent and Trademark Office (USPTO) for lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs. Continue Reading Using its proprietary Symphony™ drug discovery platform, Aria identified a lead candidate in each disease that demonstrated statistically significant efficacy in preclinical studies and a high likelihood of achieving significant efficacy in phase 2 and phase 3 trials based on Symphony's predictive capabilities. Those candidates represent novel mechanisms of action in their respective diseases and include: Aria Pharmaceuticals Advances Pipeline with Six Provisional US Patents Filed Across Three Diseases Tweet this TXR-711 , an investigational treatment for lupus: Inhibits targeted key signaling pathways that result in decreased antibody production and cytokine expression and reduces inflammation through multiple pathways and processes. TXR-1002, an investigational treatment for i diopathic p ulmonary f ibrosis (IPF): Inhibits myofibroblast proliferation, collagen, TGF-b, fibrosis, and inflammation. TXR-1210, an investigational treatment for c hronic k idney d isease (CKD): Inhibits pyroptosis and regulates IL-1 activity. Regulates renal inflammation and fibrosis as well as decreasing the release of proinflammatory cytokines and inhibiting TGF-b expression. Based on the discovery of these candidates, Aria developed new chemical entities (NCE) – two for each disease, with a total of six – representing the mechanisms of action described above to advance to clinical studies. A provisional patent application with the USPTO allows Aria Pharmaceuticals to establish intellectual property protection for its novel therapies on the filing date. Aria was able to identify novel compounds and file for provisional patents within 12-15 months for each program. "These filings represent significant development milestones for Aria and are in line with our strategic focus on moving our proprietary pipeline forward," said Andrew A. Radin, CEO of Aria Pharmaceuticals. "By analyzing multiple heterogeneous data types in one process, our drug discovery platform Symphony is proving capable of discovering novel therapies where we have high confidence in their viability as novel treatments." Aria Pharmaceuticals has built a pipeline across 18 diseases utilizing its Symphony platform for complex diseases where new treatments are needed. Using Symphony, Aria has demonstrated a 30x hit rate at in vivo efficacy milestones while mitigating risk throughout the drug development process. "We are excited and confident in the data across all of our early-stage candidates," said Anjali Pandey, Senior Vice President of Nonclinical R&D and Chemistry. "This achievement takes us closer to our goal of moving novel treatments into clinical research, and we're ready for the next steps needed for clinical success." For more information, please visit . About Aria Pharmaceuticals Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients need breakthrough treatments across many complicated diseases – they can't wait. That's why at Aria, we have redefined the drug discovery approach, saving years in the process and increasing success rates by mitigating risks throughout the drug development process. At Aria, we've shown promise across a diverse range of therapeutic areas with the ability to address over 1,000 diseases. Media Contact Serena Joshi [email protected] (650) 396-9240 SOURCE Aria Pharmaceuticals

抗体First in Class小分子药物

2022-08-30

·BioSpace

Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates

Aria Pharmaceuticals provided an update on its pipeline Tuesday, announcing it has secured six provisional patents to cover the lead drug candidates for its lupus, idiopathic pulmonary fibrosis and chronic kidney disease research programs. Aria identified lead candidates in each disease application with a “high likelihood” of achieving significant efficacy in Phase II and Phase III clinical trials, according to the company. The key takeaway is that Aria, an AI-driven organization, is now moving beyond the pre-clinical phase, CEO Andrew Radin told BioSpace Tuesday afternoon. “Part of what we’re sharing with the world is this is the last pit stop,” he said. “We tend to keep things close to the vest and we want to make sure everyone is aware of our progress.” Aria secured patents for TXR-711, an investigational treatment for lupus designed to inhibit key signaling pathways. It is expected to result in decreased antibody production and cytokine expression and reduce inflammation. For idiopathic pulmonary fibrosis, the lead candidate is TXR-1002, which is intended to inhibit myofibroblast proliferation, collagen, TGF-b, fibrosis and inflammation. TXR-1210, an investigational treatment for CKD, is designed to inhibit pyroptosis and regulate IL-1 activity, renal inflammation and fibrosis. It’s also designed to decrease the release of proinflammatory cytokines and inhibit TGF-b expression. Aria has a pipeline across 18 disease areas but the company touts its AI platform as having the potential capability to address more than 1,000 diseases. "We’ve demonstrated a 30-fold hit rate at in vivo efficacy milestones while mitigating risk throughout the drug development process," Radin said. Through its Symphony AI platform, Aria claims to be able to the time spent in drug discovery, Radin said. In some cases, this can mean selecting a drug candidate within three or four months. “By analyzing multiple heterogeneous data types in one process, [Symphony] is proving capable of discovering novel therapies where we have high confidence in their viability as novel treatments,” he said. As Aria moves forward, the science will dictate which patents and corresponding drugs will move ahead first.

抗体

100 项与 TXR-1002 相关的药物交易

登录后查看更多信息